Pembro Plus CAR T-cell Therapy in R/R in PMBCL

This research study is evaluating the combination of drugs, pembrolizumab with chimeric antigen receptor (CAR) T-cell therapy, as a possible treatment for primary mediastinal B-cell lymphoma that has recurred after prior treatment. The names of the study drugs involved in this study are: \- Pembrolizumab Standard treatment will include: * CAR T-cell therapy (either axicabtagene-ciloleucel or lisocabtagene maraleucel) * Cyclophosphamide * Fludarabine

Trial Details

NCT ID
NCT05934448
Phase
PHASE2
Sponsor
Jennifer Crombie, MD
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Pembrolizumab
  • Lymphodepletion Chemotherapy
  • Chimeric Antigen Receptor (CAR) Therapy Infusion
  • Leukapheresis
Locations (sample)
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • New York, New York, United States|40.71427,-74.00597

Key Eligibility Criteria

  • Histologically confirmed diagnosis of PMBCL, EBV+ DLBCL or THRLBCL at one of the participating institutions.
  • Availability of archival or freshly collected tumor tissue before study enrollment. If archival tissue is unavailable or is determined to be inadeq…
  • Eligible for standard of care CAR T-cell therapy with progression after at least two prior lines of therapy OR refractory to initial chemoimmunothe…
  • ECOG Performance Status of 0 or 1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →